Renal disease News and Research

RSS

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

U.S. Renal Care acquires Dialysis Corporation of America for $110.25M

U.S. Renal Care, Inc., a leading privately-held provider of outpatient dialysis services, today announced that it has completed its $110.25 million acquisition of Dialysis Corporation of America, Inc., a leading provider of outpatient kidney dialysis services. With this acquisition, USRC will provide dialysis services to approximately 5,500 patients and operate 84 dialysis centers, home and specialty hospital dialysis programs and facilities in nine states: Arkansas, Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, Texas, and Virginia.

8 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

Medicare patients may face accessibility crisis to medical care

According to an article in the June issue of the Journal of Bone and Joint Surgery (JBJS), Medicare patients - many who suffer from disabling arthritis of the hip and knee, among other age-related ailments - may end up facing an accessibility crisis to medical care.

2 Jun 2010

CMS approves Fresenius Medical Care Chronic Kidney Disease Data Registry

The U.S. Centers for Medicare and Medicaid Services (CMS) approved the Fresenius Medical Care Chronic Kidney Disease Data Registry, supported by its Acumen applications. As a participating registry in CMS's 2010 Physician Quality Reporting Initiative (PQRI), the approval of the nephrology-specific Acumen applications enables participating nephrologists to report quality outcomes directly to the PQRI program.

26 May 2010

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

25 May 2010

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

21 May 2010

Chronic kidney disease patients with depression have poorer health outcomes: Researchers

Patients with chronic kidney disease who have been diagnosed with depression are twice as likely to be hospitalized, progress to long-term dialysis treatments or die within a year as those who are not depressed, UT Southwestern Medical Center researchers have found.

20 May 2010

New study shows preoperative statin therapy protects patients undergoing elective AAA repair

Preoperative statin therapy has a protective effect on patients undergoing elective abdominal aortic aneurysm repair that reduces risk and subsequent total hospital costs according to a new study from researchers at the East Carolina Heart Institute in Greenville, North Carolina.

20 May 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

Nephros reports 57% increase in revenues for first-quarter 2010

Nephros, Inc. announced today financial results for the three months ended March 31, 2010.

14 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Rockwell Medical first-quarter sales up 17.1%

5 May 2010

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

It is estimated that between 75 and 85 percent of all Americans will suffer from low back pain and/or neck pain at some point in their lives. An estimated 12 million Americans suffer from degenerative disc disease, with over one million patients undergoing surgery each year. The cost of treating back pain is currently estimated at more than $100 billion annually in the U.S. Many patients with back pain have comorbidities that impact spine surgery.

5 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Data presented today at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) indicate that in men with high cardiovascular risk, left ventricular mass may help better predict future cardiovascular and renal outcomes, including hemodialysis.

3 May 2010

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

The Lupus Foundation of America seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease.

24 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Screening urine dipstick to diagnose chronic kidney disease in children not cost-effective

The routine use of a screening urine dipstick to diagnose chronic kidney disease in healthy children is not a cost-effective test, confirm Penn State College of Medicine researchers, who validated an American Academy of Pediatrics recommendation.